Schrödinger, Inc. has reported the appointment of Geoffrey Porges, as chief financial officer. Dr. Porges brings to Schrodinger more than 30 years of experience in executive, advisory and investment roles within the biopharmaceutical industry. As Schrodinger's CFO, he will lead all aspects of the company's financial operations and investor relations and corporate affairs activities.

He will also oversee business development and strategic planning for the company's proprietary pharmaceuticals and biopharmaceutical collaborations. The company noted that Dr. Porges joins Schrodinger from SVB Securities, where he was most recently vice chairman. From 2015 until 2022, Dr. Porges was senior managing director, director of therapeutics research and senior research analyst at SVB Securities and at Leerink prior to its acquisition by SVB Securities.

In that capacity, he led the Leerink/SVB therapeutics research team and personally provided research coverage for established and emerging diversified biopharmaceutical companies. Prior to joining SVB Securities, he was the biotechnology research analyst at Alliance Bernstein for 13 years. Earlier in his career, he held executive positions at BTG plc and Merck, including leading the commercialization of Merck's human vaccines.